Hidradenitis Suppurativa Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Inflarx, Novartis, UCB, Chemocentryx, Eli Lilly And Company, Janssen Bi

(MENAFN- GetNews)


"Hidradenitis Suppurativa Pipeline Analysis"DelveInsight's,“Hidradenitis Suppurativa - Pipeline Insight, 2025,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, over 24 key companies are actively engaged in developing more than 24 treatment therapies for Hidradenitis Suppurativa, reflecting a robust and evolving pipeline.

Hidradenitis Suppurativa Overview:

Hidradenitis suppurativa (HS), also called acne inversus, is a chronic inflammatory skin condition marked by deep nodules, abscesses, draining tunnels, and scarring. These lesions typically form in areas where skin rubs together and where apocrine glands are abundant, such as the underarms, groin, perianal, perineal, and beneath the breasts.

The disease develops due to blockage and rupture of abnormal hair follicles, which releases keratin and bacteria into the dermis. This initiates an immune reaction involving neutrophils and lymphocytes, often leading to abscesses and damage to the hair follicles and surrounding tissue.

There is currently no cure for HS, and its outlook can vary, often deteriorating with delayed diagnosis or insufficient treatment. Factors like smoking and obesity can worsen the condition, emphasizing the need for timely care and lifestyle changes. Successful management typically requires a team-based approach involving dermatologists, surgeons, and other specialists.

Request for a detailed insights report on Hidradenitis Suppurativa pipeline insights

"Hidradenitis Suppurativa Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hidradenitis Suppurativa Therapeutics Market.

Key Takeaways from the Hidradenitis Suppurativa Pipeline Report

• DelveInsight's Hidradenitis Suppurativa pipeline report depicts a robust space with 24+ active players working to develop 24+ pipeline therapies for Hidradenitis Suppurativa treatment.

• Key Hidradenitis Suppurativa companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics, and others are evaluating new drugs for Hidradenitis Suppurativa to improve the treatment landscape.

• Promising Hidradenitis Suppurativa pipeline therapies in various stages of development include Vilobelimab, Secukinumab, Avacopan, Imsidolimab, Spesolimab, and others.

Recent breakthroughs in the Hidradenitis Suppurativa Pipeline Segment:

• In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 effectively suppressed tumor growth in mesothelioma by inducing autophagy and promoting cellular senescence. The preclinical findings indicate that APG-2449, when paired with CDK4/6 inhibitors, could offer therapeutic promise for mesothelioma and support further clinical investigation.

• Also in April 2022, AnaptysBio, a clinical-stage biotech company developing antibody therapies for inflammatory diseases, shared updates on its anti-IL-36R antibody, imsidolimab (formerly ANB019). This investigational therapy is being developed for skin disorders such as generalized pustular psoriasis (GPP) and moderate-to-severe hidradenitis suppurativa (HS), with top-line results from the HARP Phase 2 trial in HS expected in the third quarter of 2022.

• In February 2022, InflaRx, a biopharmaceutical company focused on anti-inflammatory treatments targeting the complement system, released new data on vilobelimab (IFX-1), an anti-C5a antibody. The data showed significantly higher baseline C5a levels in patients with moderate-to-severe Hurley Stage II and III HS compared to healthy controls, underlining its potential as a therapeutic option for hidradenitis suppurativa.

Hidradenitis Suppurativa Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Hidradenitis Suppurativa Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hidradenitis Suppurativa market.

Download our free sample page report on Hidradenitis Suppurativa pipeline insights

Hidradenitis Suppurativa Emerging Drugs

• Vilobelimab: InflaRx

• Secukinumab: Novartis

• Avacopan: ChemoCentryx

• Imsidolimab: AnaptysBio

• Spesolimab: Boehringer Ingelheim

Hidradenitis Suppurativa Companies

Over 24 leading companies are currently engaged in developing treatments for Hidradenitis Suppurativa (HS), with InflaRx's drug candidate being the most advanced, currently in Phase III clinical trials.

DelveInsight's report covers around 24+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Hidradenitis Suppurativa Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hidradenitis Suppurativa Therapies and Key Companies: Hidradenitis Suppurativa Clinical Trials and advancements

Hidradenitis Suppurativa Pipeline Therapeutic Assessment

. Hidradenitis Suppurativa Assessment by Product Type

. Hidradenitis Suppurativa By Stage

. Hidradenitis Suppurativa Assessment by Route of Administration

. Hidradenitis Suppurativa Assessment by Molecule Type

Download Hidradenitis Suppurativa Sample report to know in detail about the Hidradenitis Suppurativa treatment market @ Hidradenitis Suppurativa Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Hidradenitis Suppurativa Current Treatment Patterns

4. Hidradenitis Suppurativa - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Hidradenitis Suppurativa Late-Stage Products (Phase-III)

7. Hidradenitis Suppurativa Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hidradenitis Suppurativa Discontinued Products

13. Hidradenitis Suppurativa Product Profiles

14. Hidradenitis Suppurativa Key Companies

15. Hidradenitis Suppurativa Key Products

16. Dormant and Discontinued Products

17. Hidradenitis Suppurativa Unmet Needs

18. Hidradenitis Suppurativa Future Perspectives

19. Hidradenitis Suppurativa Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Hidradenitis Suppurativa Pipeline Reports Offerings

MENAFN04082025003238003268ID1109883614